Publication | Closed Access

Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial

Antimicrobial SusceptibilityAntibioticsPhase 2Bβ-Lactam-treated PatientsPlacebo-controlled TrialAntimicrobial ChemotherapyMicrobiologyInfection ControlAntimicrobial PharmacokineticsAntimicrobial PharmacodynamicsMedicineBacterial PathogensClinical MicrobiologyAntimicrobial Resistance